bl-1021
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01121380)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Toll-like receptor 9INHIBITOR
TLR9 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)CCCN- Mol. weight
- 348.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL490932 ↗
- ChEMBLCHEMBL1187120 ↗
Also known as
- bl-1021
- bl-1021
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01121380 | Phase 1 | Jun 1, 2011 | BioLineRx, Ltd., Hebrew University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioLineRx, Ltd. | For profit | 1 | 1 | 1 | 2011 |
| Hebrew University | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1